Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Penile Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1

Interventions

Cyclophosphamide 6pembrolizumab 5Cisplatin 4sargramostim 3Pemetrexed 3Decitabine 3Celecoxib 3fludarabine 2belinostat 2SS1(dsFv)PE38 2Quality of Life 2Plicamycin 2Nivolumab 2Ipilimumab 2FANG vaccine 2Drug Therapy 2perflutren 1olaparib 1niraparib 1iodixanol 1incomplete Freund's adjuvant 1fludarabine phosphate 1dostarlimab 1anetumab ravtansine 1aldesleukin 1alanosine 1Vorinostat 1Valacyclovir 1UV1 vaccine 1Tumor Burden 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × BAY 1895344 × Other solid neoplasm × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡